Pataday

Manufacturer
Physicians Total Care, Inc.
Effective date
2011-01-05
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:11:01

Label at a glance#

ProductPataday
Active ingredientOLOPATADINE HYDROCHLORIDE
Label structure11 sections

Indications and uses

PATADAY™ solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Dosage and administration

The recommended dose is one drop in each affected eye once a day.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

PATADAY™ (olopatadine hydrochloride ophthalmic solution) 0.2% is a sterile ophthalmic solution containing olopatadine for topical administration to the eyes.

Olopatadine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 373.88 and a molecular formula of C21H23NO3· HCl. The chemical structure is presented below:

image of chemical structureimage of chemical structure

Chemical Name: 11-[(Z)-3-(Dimethylamino) propylidene]-6-11-dihydrodibenz[b,e] oxepin-2-acetic acid, hydrochloride

Each mL of PATADAY™ solution contains: Active: 2.22 mg olopatadine hydrochloride equivalent to 2 mg olopatadine. Inactives: povidone; dibasic sodium phosphate; sodium chloride; edetate disodium; benzalkonium chloride 0.01% (preservative) hydrochloric acid / sodium hydroxide (adjust pH); and purified water.

It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Olopatadine is a relatively selective histamine H1 antagonist and an inhibitor of the release of histamine from the mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. Olopatadine is devoid of effects on alpha-adrenergic, dopaminergic, and muscarinic type 1 and 2 receptors.

Systemic bioavailability data upon topical ocular administration of PATADAY™ solution are not available. Following topical ocular administration of olopatadine 0.15% ophthalmic solution in man, olopatadine was shown to have a low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (< 0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The elimination half-life in plasma following oral dosing was 8 to 12 hours, and elimination was predominantly through renal excretion. Approximately 60 - 70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine.

CLINICAL STUDIES

CLINICAL STUDIES SECTION

Results from clinical studies of up to 12 weeks duration demonstrate that PATADAY™ solution when dosed once a day is effective in the treatment of ocular itching associated with allergic conjunctivitis.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

PATADAY™solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hypersensitivity to any components of this product.

WARNINGS

WARNINGS SECTION

For topical ocular use only. Not for injection or oral use.

PRECAUTIONS

PRECAUTIONS SECTION

Information for Patients

As with any eye drop, to prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Patients should be advised not to wear a contact lens if their eye is red.

PATADAY™ (olopatadine hydrochloride ophthalmic solution) 0.2% should not be used to treat contact lens related irritation. The preservative in PATADAY™ solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red, should be instructed to wait at least ten minutes after instilling PATADAY™ (olopatadine hydrochloride ophthalmic solution) 0.2% before they insert their contact lenses.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 µL drop size and a 50 kg person, these doses were approximately 150,000 and 50,000 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of approximately 100,000 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of approximately 15,000 times the MROHD level.

PregnancyTeratogenic effects: Pregnancy Category C

Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Nursing Mothers

Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when PATADAY™ (olopatadine hydrochloride ophthalmic solution) 0.2% is administered to a nursing mother.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

Geriatric Use

No overall differences in safety and effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%.

The following adverse experiences have been reported in 5% or less of patients:

Ocular: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.

Non-ocular: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.

Some of these events were similar to the underlying disease being studied.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended dose is one drop in each affected eye once a day.

HOW SUPPLIED

HOW SUPPLIED SECTION

PATADAY™(olopatadine hydrochloride ophthalmic solution) 0.2% is supplied in a white, oval, low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and a white polypropylene cap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.

NDC 54868-6222-0        2.5 mL fill in 4 mL oval bottle

Storage

Store at 2oC to 25oC (36oF to 77oF)

U.S. Patents Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805; 6,995,186

Rx Only

© 2006 Alcon, Inc.


Relabeling of "Additional" barcode label by:
Physicians Total Care, Inc.
Tulsa, OK       74146


PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PATADAY™(olopatadine hydrochloride ophthalmic solution) 0.2%

2.5 mL

image of package labelimage of package label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1111343olopatadine HCl 0.2 % Ophthalmic SolutionPSN1
1111345Pataday Once Daily 0.2 % Ophthalmic SolutionPSN1
1111345olopatadine 2 MG/ML Ophthalmic Solution [Pataday]SBD1
1111343olopatadine 2 MG/ML Ophthalmic SolutionSCD1
1111343olopatadine 0.2 % Ophthalmic SolutionSY1
1111343olopatadine 2 MG/ML (as olopatadine HCl 2.22 MG/ML) Ophthalmic SolutionSY1
1111345Pataday 0.2 % Ophthalmic SolutionSY1
1111345Pataday 2 MG/ML (olopatadine HCl 2.22 MG/ML) Ophthalmic SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
OLOPATADINE Pharmacologic Class Indexing4Indexing - Pharmacologic Class20220128

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
624001e0-0eba-4aac-a60c-c2ecb37d4f08Product name120220927
abab02bf-82c6-4b6c-8cb4-2ee39055aeb1Product name320210312
ee1438f7-d464-b7de-1b3a-aae378f7d672Product name820200121
4101b788-a943-3f81-6947-4acf7be2af4dProduct name420190703
ca2d4a1a-2b5b-4256-9aad-735e9282b3eeProduct name120150323

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
54868-6222-02019-09-24C16284748780-19350213a-431c-c013-e053-90daa90a1393ee6e2161-789b-4ba0-b234-d4b36fe41c94

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-6222-0Pataday2.5 mL in 1 BOTTLE, PLASTICSOLUTION/ DROPS2.51

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-6222PATADAY (OLOPATADINE HYDROCHLORIDE) SOLUTION/ DROPS [PHYSICIANS TOTAL CARE, INC.]11 package rows20110106_ee6e2161-789b-4ba0-b234-d4b36fe41c94.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-6222-0ML - Milliliter54868-6222d1018edd-12bf-4031-92aa-d79f620b0b7f12012-07-24
0065-0272-25ML - Milliliter0065-0272cad510e4-8a94-4704-8c78-69e9daf66a0e12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
OLOPATADINE HYDROCHLORIDEACTIVE INGREDIENT2XG66W44KF1
OLOPATADINEACTIVE MOIETYD27V6190PM1
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W71
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K1
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CB1
POVIDONEINACTIVE INGREDIENTFZ989GH94E1
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8X1
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I1
SODIUM PHOSPHATE, DIBASICINACTIVE INGREDIENTGR686LBA741
WATERINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-622254868-6222-0
0065-02720065-0272-25

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 11 · 601 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, EMULSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
POVIDONEPOVIDONEFZ989GH94ETABLET, FILM COATED, EXTENDED RELEASE / ORAL17 mgExact identifier — unii candidate
30 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION, EXTENDED RELEASE / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XPOWDER, DENTIFRICE / DENTAL0.03 mg/mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SOLUTION / INTRATHECAL1.35 mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSPONGE / TOPICALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SOLUTION / SUBCUTANEOUS1486 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IDROPS / OPHTHALMICNAExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / SUBMUCOSALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / URETHRALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION, CONCENTRATE / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBDROPS / NASAL10 mlExact identifier — unii candidate
148 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION / ORAL432 mgExact identifier — unii candidate
77 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSYSTEM / IONTOPHORESIS0.1 mgExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRADISCALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION / OPHTHALMIC2 %w/vExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / AURICULAR (OTIC)0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUSNAExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / ORAL1126 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XCREAM / TOPICAL0.4 %w/wExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBLIQUID / NASALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION, SUSPENSION / INTRA-ARTICULAR26 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION / ORAL148 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IFILM, EXTENDED RELEASE / TRANSDERMAL0.85 mgExact identifier — unii candidate
174 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KTABLET, COATED / ORAL0.21 mgExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / NASAL20 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSOLUTION/ DROPS / TOPICAL0.86 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRALESIONAL0.9 %w/vExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / RECTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION/ DROPS / AURICULAR (OTIC)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINHALANT / RESPIRATORY (INHALATION)3 mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBLIQUID / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSPRAY / RESPIRATORY (INHALATION)0.05 %w/wExact identifier — unii candidate
77 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBCUTANEOUS1037 mgExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION / ORAL223 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, COATED / ORAL0.08 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XINJECTION / INTRABURSAL9 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVENOUS456 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAUDALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAMUSCULAR176 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSUSPENSION / ENDOTRACHEAL7.6 mgExact identifier — unii candidate
134 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBTABLET / ORAL2.32 mgExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XTABLET / ORAL231 mgExact identifier — unii candidate
134 equally ranked IID candidates
SODIUM CHLORIDESODIUM CHLORIDE451W47IQ8XSYSTEM / IONTOPHORESIS6 mgExact identifier — unii candidate
134 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION / INTRACARDIAC2 mgExact identifier — unii candidate
77 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS0.18 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74INJECTION / INTRAMUSCULAR40 mgExact identifier — unii candidate
14 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SPRAY, METERED / NASAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS19 mgExact identifier — unii candidate
77 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SHAMPOO / TOPICAL0.2 %w/wExact identifier — unii candidate
24 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N021545-001PATADAY ONCE DAILY RELIEFOLOPATADINE HYDROCHLORIDEEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22d4dbc9d85df4…
2026-10-15 13:18:302026-09N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22c2088c7a36db…
2026-09-14 22:38:342026-08N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-2284e616aacf4f…
2026-08-18 06:07:402026-07N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-2231067a03dcf5…
2025-08-23 18:47 UTC2025-08N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-226a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-2203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-222680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-225bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-2279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-221e350fbaab3a…
2024-05-31 18:47 UTC2024-05N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-228072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-225c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-225d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-224b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N021545-001PATADAYEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS2004-12-2274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-2287673890dc5c…
2021-03-12 10:30 UTC2021-03N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-225aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-228869cabd3fbd…
2020-11-12 02:37 UTC2020-11N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22c0c555d07b60…
2019-12-14 00:12 UTC2019-12N021545-001PATADAYEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS2004-12-223f01610625f2…
2019-09-15 20:21 UTC2019-09N021545-001PATADAYEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS2004-12-22b00525d2431f…
2019-07-19 19:46 UTC2019-07N021545-001PATADAYEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICATRLD, RS2004-12-22ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-226a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-221c564ffb4f44…
2023-12-20 04:57 UTC2023-12N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-229b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-223f0d92c62455…
2023-05-13 08:27 UTC2023-05N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-22053a50430f4f…
2023-01-26 05:58 UTC2023-01N021545-001PATADAY ONCE DAILY RELIEFEQ 0.2% BASESOLUTION/DROPS / OPHTHALMICRLD, RS2004-12-223bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2019-12-13 00:20 UTC2019-12N021545-001AT174a2ff9319b5…
2019-12-14 00:12 UTC2019-12N021545-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09N021545-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07N021545-001AT1ea99ee380514…

Observed Orange Book patent history#

Captured, Edition, Application-product table
CapturedEditionApplication-productPatentExpirationUse codeCoverage / statusSubmission dateSource SHA-256
2019-12-13 00:20 UTC2019-12N021545-00174026092022-06-19Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N021545-0017402609*PED2022-12-19Pediatric extension74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N021545-00169951862023-11-12U-765Drug product74a2ff9319b5…
2019-12-13 00:20 UTC2019-12N021545-0016995186*PED2024-05-12Pediatric extension74a2ff9319b5…
2019-12-14 00:12 UTC2019-12N021545-00174026092022-06-19Drug product3f01610625f2…
2019-12-14 00:12 UTC2019-12N021545-0017402609*PED2022-12-19Pediatric extension3f01610625f2…
2019-12-14 00:12 UTC2019-12N021545-00169951862023-11-12U-765Drug product3f01610625f2…
2019-12-14 00:12 UTC2019-12N021545-0016995186*PED2024-05-12Pediatric extension3f01610625f2…
2019-09-15 20:21 UTC2019-09N021545-00174026092022-06-19Drug productb00525d2431f…
2019-09-15 20:21 UTC2019-09N021545-0017402609*PED2022-12-19Pediatric extensionb00525d2431f…
2019-09-15 20:21 UTC2019-09N021545-00169951862023-11-12U-765Drug productb00525d2431f…
2019-09-15 20:21 UTC2019-09N021545-0016995186*PED2024-05-12Pediatric extensionb00525d2431f…
2019-07-19 19:46 UTC2019-07N021545-00174026092022-06-19Drug productea99ee380514…
2019-07-19 19:46 UTC2019-07N021545-0017402609*PED2022-12-19Pediatric extensionea99ee380514…
2019-07-19 19:46 UTC2019-07N021545-00169951862023-11-12U-765Drug productea99ee380514…
2019-07-19 19:46 UTC2019-07N021545-0016995186*PED2024-05-12Pediatric extensionea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
00904221-c0c7-49bd-b00a-8689a2a5a386ee6e2161-789b-4ba0-b234-d4b36fe41c942011-01-05Warnings, Adverse reactionsExact identifier
spl id: 00904221-c0c7-49bd-b00a-8689a2a5a386
spl set id: ee6e2161-789b-4ba0-b234-d4b36fe41c94

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.